The Current Air Quality Crisis The state of air quality today is alarming, affecting not just major cities but also small ...

The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...

Betterbrand is a PharmD-founded lung health supplement company established in 2019. BetterLungs® products combine ...

AstraZeneca’s experimental drug tozorakimab has shown promising results in late-stage trials, reducing flare-ups in patients with chronic obstructive pulmonary disease and boosting investor optimism ...

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients ...

AstraZeneca shares rose after the company said a drug candidate met the primary goal in two late-stage trials for a deadly lung disease, clearing the path to seek approval from regulators. The U.K.

Results from 2 COPD phase 3 trials suggest that targeting the IL-33 pathway with tozorakimab delivers meaningful clinical ...

March 27 () - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful reduction in ...

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, ...

GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms in two large trials. The drug, ...